Objectives: Postoperative RT is generally recommended for laryngeal carcinomas (LSCCs) at high risk of recurrence after surgery. There are currently no clinicopathological parameters available to predict response to such adjuvant RT in LSCC, and only a few potentially predictive biomarkers have been investigated. Nm23-H1 protein is reportedly related to the tumor cells’ metastatic potential, and low nm23-H1 expression levels in human carcinomas often correlate with a poor prognosis. The novel aim of the present study was to investigate the prognostic value of nm23-H1 expression and subcellular localization in a series of patients given postoperative RT for LSCC. Design: Retrospective clinicopathological investigation. Setting: Academic tertiary referral center. Patients: 28 consecutive patients given postoperative RT for LSCC. Main outcome measure: Image analysis of immunohistochemical reactions to measure nm23-H1 total and nuclear expression levels. Results: Disease-free survival (DFS) was significantly shorter among LSCC patients with total nm23-H1 levels <50.0% (p=0.03); the LSCC recurrence rate was higher in patients with total nm23-H1 levels <50.0% (statistical trend, p=0.07). The disease recurrence rate was significantly higher (p=0.021) and the DFS shorter (statistical trend, p=0.052) among LSCC patients a nuclear nm23-H1 levels <5.0%. The loco-regional recurrence-risk ratio in LSCC patients with nuclear nm23-H1 levels <5.0% was 9.16. Conclusions: Nm23-H1 warrants further investigation for its potential role as a predictive biomarker with a view to providing tailored treatments after surgery, such as combinations of chemotherapy and RT instead of RT alone, in patients whose LSCCs have low or no nm23-H1 expression.
A prognostic role for nm23-H1 in laryngeal carcinoma treated with postoperative radiotherapy: an introductory investigation
BLANDAMURA, STELLA;Agostini, M;Lovato, A;Favaretto, N;STAFFIERI, ALBERTO;MARIONI, GINO
2013
Abstract
Objectives: Postoperative RT is generally recommended for laryngeal carcinomas (LSCCs) at high risk of recurrence after surgery. There are currently no clinicopathological parameters available to predict response to such adjuvant RT in LSCC, and only a few potentially predictive biomarkers have been investigated. Nm23-H1 protein is reportedly related to the tumor cells’ metastatic potential, and low nm23-H1 expression levels in human carcinomas often correlate with a poor prognosis. The novel aim of the present study was to investigate the prognostic value of nm23-H1 expression and subcellular localization in a series of patients given postoperative RT for LSCC. Design: Retrospective clinicopathological investigation. Setting: Academic tertiary referral center. Patients: 28 consecutive patients given postoperative RT for LSCC. Main outcome measure: Image analysis of immunohistochemical reactions to measure nm23-H1 total and nuclear expression levels. Results: Disease-free survival (DFS) was significantly shorter among LSCC patients with total nm23-H1 levels <50.0% (p=0.03); the LSCC recurrence rate was higher in patients with total nm23-H1 levels <50.0% (statistical trend, p=0.07). The disease recurrence rate was significantly higher (p=0.021) and the DFS shorter (statistical trend, p=0.052) among LSCC patients a nuclear nm23-H1 levels <5.0%. The loco-regional recurrence-risk ratio in LSCC patients with nuclear nm23-H1 levels <5.0% was 9.16. Conclusions: Nm23-H1 warrants further investigation for its potential role as a predictive biomarker with a view to providing tailored treatments after surgery, such as combinations of chemotherapy and RT instead of RT alone, in patients whose LSCCs have low or no nm23-H1 expression.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
